Neuron23 logo

Neuron23

Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we treat Parkinson’s.

28 employees · est. 2018 · South San Francisco, United...

VS
T3D Therapeutics, Inc. logo

T3D Therapeutics, Inc.

Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegenerative diseases.

12 employees · est. 2013 · Durham, United States

T3D Therapeutics, Inc. is the older company (2018 vs 2013).

Side-by-Side Comparison

Neuron23 T3D Therapeutics, Inc.
Founded
2018 2013 older
Headquarters
South San Francisco, United States Durham, United States
Employees
28 12
Industry
Not tracked yet Biotechnology
Funding Stage
Series D Series Unknown
Total Funding
$230.00M $40.31M
Funding Rounds
4 8
Services
Development of precision medicine for Parkinson's Disease, Clinical trials for novel therapeutic approaches, Research and development in neuroimmunology and neuroscience Not tracked yet
Target Customers
Patients with Parkinson's Disease, Healthcare providers specializing in neurology, Pharmaceutical and biotechnology investors Not tracked yet
Taxonomy
Precision Medicine, Parkinson's Disease, Neurodegenerative Diseases, Human Genetics, Biomarker Platform, Drug Discovery, Neurological Diseases, Alzheimer's Disease, Clinical-stage Biotechnology, Hyperactive LRRK2, Patient-centered Approach, Neuroinflammatory Diseases, Autoimmune Diseases Alzheimer's Disease, Neurodegenerative Diseases, Drug Development, T3D-959, Disease-modifying, Breakthrough Medicine, Clinical Studies, Huntington's Disease, Therapeutic Utility, Potential Treatment, Disease Reversal
Website
neuron23.com t3dtherapeutics.com
Neuron23 logo

About Neuron23

Neuron23, founded in 2018, is a clinical-stage biotechnology company based in the United States. The company is pioneering advancements in precision medicine, specifically targeting Parkinson’s disease driven by hyperactive LRRK2. By integrating cutting-edge science with human genetics and its propr...

T3D Therapeutics, Inc. logo

About T3D Therapeutics, Inc.

T3D Therapeutics, Inc. is a biotechnology startup founded in 2013, based in the United States. The company is dedicated to developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegenerative diseases. Their lead drug product candidate, T3D-959, is positioned as...

We will tell you when either one moves

BounceWatch watches Neuron23 and T3D Therapeutics, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Neuron23 and T3D Therapeutics, Inc. — by email.

Frequently Asked Questions

Neuron23 — Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we treat Parkinson’s.. T3D Therapeutics, Inc. — Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegenerative diseases.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Neuron23 has raised $230.00M while T3D Therapeutics, Inc. has raised $40.31M.
Neuron23 and T3D Therapeutics, Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Neuron23 with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Neuron23 on 31 Mar 2026, and T3D Therapeutics, Inc. on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy